Navigation Links
Superbug MRSA identified in US wastewater treatment plants
Date:11/5/2012

College Park, Md. A team led by researchers at the University of Maryland School of Public Health has found that the "superbug" methicillin-resistant Staphylococcus aureus (MRSA) is prevalent at several U.S. wastewater treatment plants (WWTPs). MRSA is well known for causing difficult-to-treat and potentially fatal bacterial infections in hospital patients, but since the late 1990s it has also been infecting otherwise healthy people in community settings.

"MRSA infections acquired outside of hospital settings known as community-acquired MRSA or CA-MRSA are on the rise and can be just as severe as hospital-acquired MRSA. However, we still do not fully understand the potential environmental sources of MRSA or how people in the community come in contact with this microorganism," says Amy R. Sapkota, assistant professor in the Maryland Institute for Applied Environmental Health and research study leader. "This was the first study to investigate U.S. wastewater as a potential environmental reservoir of MRSA."

Because infected people can shed MRSA from their noses and skin and through their feces, wastewater treatment plants are a likely reservoir for the bacteria. Swedish researchers have previously identified the presence of MRSA in WWTPs in Sweden, and this new UMD-led study confirms the presence of MRSA in U.S. facilities. The study was published in the November issue of the journal Environmental Health Perspectives.

The research team, including University of Maryland School of Public Health and University of Nebraska Medical Center researchers, collected wastewater samples throughout the treatment process at two Mid-Atlantic and two Midwestern WWTPs. These plants were chosen, in part, because treated effluent discharged from these plants is reused as "reclaimed wastewater" in spray irrigation activities. The researchers were interested in whether MRSA remained in the effluent.

They found that MRSA, as well as a related pathogen, methicillin-susceptible Staphylococcus aureus (MSSA), were present at all four WWTPs, with MRSA in half of all samples and MSSA in 55 percent. MRSA was present in 83 percent of the influent the raw sewage at all plants, but the percentage of MRSA- and MSSA-positive samples decreased as treatment progressed. Only one WWTP had the bacteria in the treated water leaving the plant, and this was at a plant that does not regularly use chlorination, a tertiary step in wastewater treatment.

Ninety-three percent of the MRSA strains that were isolated from the wastewater and 29 percent of MSSA strains were resistant to two or more classes of antibiotics, including several that the U.S. Food and Drug Administration has specifically approved for treating MRSA infections. At two WWTPs, MRSA strains showed resistance to more antibiotics and greater prevalence of a gene associated with virulence at subsequent treatment stages, until tertiary chlorination treatment appeared to eliminate all MRSA. This suggests that while WWTPs effectively reduce MRSA and MSSA from influent to effluent, they may select for increased antibiotic resistance and virulence, particularly at those facilities that do not employ tertiary treatment (via chlorination).

"Our findings raise potential public health concerns for wastewater treatment plant workers and individuals exposed to reclaimed wastewater," says Rachel Rosenberg Goldstein, environmental health doctoral student in the School of Public Health and the study's first author. "Because of increasing use of reclaimed wastewater, further research is needed to evaluate the risk of exposure to antibiotic-resistant bacteria in treated wastewater."


'/>"/>

Contact: Kelly Blake
kellyb@umd.edu
301-405-9418
University of Maryland
Source:Eurekalert

Related biology news :

1. Hunt for superbugs in Australian animals
2. Distinct developmental patterns identified in children with autism during their first 3 years
3. Australian shipping emissions identified
4. The end of an era? Branding horses does not enable them to be identified
5. Nematodes with pest-fighting potential identified
6. Unusual weather events identified during the Black Saturday bushfires
7. Target for potent first-strike influenza drugs identified
8. Skin cancer identified for the first time in wild fish populations
9. New cause of child blindness identified
10. New therapeutic target for prostate cancer identified
11. Parkinsons disease gene identified with help of Mennonite family: UBC-VCH research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring announced that after ... secured the final acceptance by all three (3) ... Systems (MAS) installed. Furthermore, Securus will have contracts ... by October, 2016. MAS distinguishes between legitimate wireless ...
(Date:6/9/2016)... attendance control systems is proud to announce the introduction of fingerprint attendance control software, ... employees are actually signing in, and to even control the opening of doors. ... ... ... Photo - http://photos.prnewswire.com/prnh/20160609/377487 ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
Breaking Biology News(10 mins):
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
(Date:6/23/2016)... ... , ... STACS DNA Inc., the sample tracking software company, today announced that ... joined STACS DNA as a Field Application Specialist. , “I am thrilled that ... of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology: